Term ends Nov 7, 2036 · Medium confidence
20-year base term ends Nov 7, 2036
Why Medium: A parent in the chain could not be resolved.
Held by Neurobo Pharmaceuticals, Inc.
Filed Jan 26, 2017 as application 15/416,911 · Granted Dec 26, 2017
Base term, 20 years from filing
Today
2016
2036
Clock starts
Nov 7, 2016
Nov 7, 2016
Term ends
Nov 7, 2036
Nov 7, 2036
Granted
Dec 26, 2017
Dec 26, 2017
base term
fee events
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 7, 2016, when application PCT/US2016/060837, the earliest non-provisional in its chain, was filed (this one was filed Jan 26, 2017); a parent in its chain could not be resolved (the next row) | Nov 7, 2036 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 7, 2036 | Medium confidence |
Partial family
| Application PCT/US2016/060837 | PCT application no patent term | no patent term |
| US 9,849,104 | this patent Nov 2036 | Nov 2036 |
| Application 15/424,620 | Abandoned not computed | not computed |
| US 10,449,154 | In force Nov 2036 | Nov 2036 |
Partial: 1 of the 4 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 23, 2017 Reel 41700, frame 430 | Bisgaier, Charles L.; Oniciu, Daniela Carmen | Gemphire Therapeutics Inc. | Assignment of Assignor's Interest |
| Mar 16, 2020 Reel 52180, frame 627 | Gemphire Therapeutics Inc. | Neurobo Pharmaceuticals, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Nov 2036
Term ends Nov 7, 2036. Maintenance fees still fall due before then
Citations
21
later US patents cite this one
That is top 25% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.